Health & bio

FDA Proposes Excluding GLP-1 from 503B Bulk Drugs (April 30)

Semaglutide, tirzepatide, and liraglutide removed from 503B bulk drug list proposal, signaling compounding era conclusion.

Primary sources · 1
IAPAM
← View the full 2026-05-01 (Fri) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →